Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report.
Respir Med Case Rep
; 34: 101560, 2021.
Article
em En
| MEDLINE
| ID: mdl-34868871
A 71-year-old female patient with B-cell depletion due to treatment with an anti-CD20 monoclonal antibody was admitted for worsening COVID-19. Overall, she had persistent viral shedding, worsening respiratory failure, and progressive pneumonia that did not improve despite dexamethasone and antibiotic therapy. After administration of bamlanivimab, a monoclonal antibody with high affinity for the receptor-binding domain of the SARS-CoV-2 spike protein, inflammatory markers rapidly decreased, SARS-CoV2 RT-PCR became negative, and the patient improved clinically and radiologically. In conclusion, we demonstrated successful treatment of prolonged COVID-19 in a patient with severe B-cell aplasia with a virus-neutralizing monoclonal antibody.
B-Cell aplasia; BMI, body-mass index; COVID-19; COVID-19, Coronavirus Disease 2019; CRP, C-reactive protein; CT, computed tomography; ICU, intensive care unit; IL-2, interleukin 2; Immunodeficiency; Monoclonal antibodies; NK, natural killer; SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2; TNF-alpha, Tumor necrosis factor
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article